Glioblastoma (GBM) remains a lethal disease with poor prognosis despite significant recent discoveries in disease pathogenesis, and novel therapeutic strategies are desperately needed.
Statement of Translational Relevance
Glioblastoma (GBM) remains a lethal disease with poor prognosis despite significant recent discoveries in disease pathogenesis, and novel therapeutic strategies are desperately needed.
Myc is a potent oncogene that is overactive in a subset of GBM and drives multiple cancerrelated phenotypes including altered metabolism to support rapid cell growth and proliferation.
Here, we identify a therapeutic strategy that exploits the Myc-induced glycolytic dependency present in a subset of Myc and N-Myc-driven GBM. We show that Myc increases glycolytic flux in GBM cells, and that this metabolic shift generates a vulnerability to glycolytic inhibition. We identify inhibitors of the NAD+ salvage pathway rate-limiting enzyme nicotinamide phosphoribosyl-transferase (NAMPT), which attenuate glycolysis to induce cytotoxicity, as a highly potent and selective therapeutic strategy for MYC/MYCN amplified GBM. As NAMPT inhibitors have entered clinical development, potential exists for rapid clinical translation in a genetically defined subset of GBM. 
INTRODUCTION
The MYC gene family (MYC, MYCN and MYCL) consists of potent oncogenes that play critical roles in the pathogenesis of diverse types of human cancers (1, 2) . The Myc oncoprotein contributes to malignancy by various mechanisms, including driving cellular proliferation, blocking differentiation, facilitating chromosomal instability, increasing cell migration and inducing angiogenesis (1, 2) . In glioblastoma (GBM), Myc enhances the self-renewal capacity of glioma stem-like/tumor neurosphere (tumorsphere) cells and maintains their tumorigenic potential (3) (4) (5) (6) . High-level amplification of the MYC and MYCN genes are observed in a subset of GBM (7) (8) (9) (10) (11) . Myc is therefore a compelling therapeutic target in GBM.
Despite extensive efforts, direct inhibition of the Myc transcription factor has remained a challenge. Several indirect strategies that selectively target the pleiotropic Myc-driven downstream effects have recently shown promise, including small molecule inhibitors of BET chromatin adapters (12, 13) , Chk1 (14) and CDK7 (15) . Another potential Myc-specific target is the Myc-reprogrammed metabolic state, which is evident in GBM (16) (17) (18) . Deregulated Myc has been shown to increase glycolysis and glutaminolysis to support the increased biosynthetic demand of rapidly proliferating cancer cells, and the altered cell metabolism may render Mycdriven cancers vulnerable to strategic nutrient deprivation (16, 19 ).
Here, we tested whether inhibition of the Myc-induced glycolytic drive would be a selective strategy for Myc-driven GBM. We confirmed that Myc increases glycolytic flux in GBM cells and found that Myc generates a dependency on glycolysis for survival. Using a panel of patientderived GBM tumorsphere lines (20, 21) we found glycolytic inhibition to be strikingly selective for lines with highly amplified MYC/MYCN. We identified small molecule inhibitors of the NAD+ salvage enzyme nicotinamide phosphoribosyl-transferase (NAMPT), which mediates cytotoxicity
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MATERIALS AND METHODS

Creation of GBM tumorsphere Lines, Cell culture and Reagents
To create GBM tumorsphere lines, fresh patient GBM surgical specimens were dissociated and cultured in serum-free neural stem cell medium, which enriches for tumor-initiating cells (20, 21) . All tumorsphere lines were cryopreserved at passage number 3 or less prior to use for in vitro experiments. For genetic manipulation, lines passaged <10 times were used. All tumor samples were collected with patient consent under protocols approved by the Massachusetts General Hospital (MGH) Institutional Review Board. All tumors were confirmed to be glioblastoma by formal pathological review. U87, H1975, D283 Med, IMR-32, Daoy, and Raji cell lines were obtained from American Type Culture Collection (ATCC) and were cultured using ATCC-formulated EMEM (for IMR-32, D283 Med, and Daoy), ATCC-formulated RPMI-1640 (for H1975 and Raji), or DMEM (for U87) . Kelly was obtained from Sigma Aldrich and cultured with EMEM. UACC257 was a gift from David E. Fisher (MGH) and cultured with DMEM. Normal human astrocytes (NHA) were obtained from ScienCell and cultured in DMEM. All standard cell line media were supplemented with 10% fetal bovine serum (FBS) and Penicillin-streptomycinAmphotericin B. FK866, nicotinamide mononucleotide (NMN), nicotinic acid (NA), nicotinamide adenine dinucleotide (NAD+), and 2-deoxyglucose (2-DG) were purchased from Sigma Aldrich.
GMX1778 was purchased from Cayman Chemical.
U87-Myc Cell Line Generation
Research. 293T cells were co-transfected with lentivirus vectors containing MYC (pCDH-puro-cMYC, Plasmid #46970, Addgene) or GFP (pCDH-CMV-MCS-EF1-copGFP, CD511B-1, System Bioscience), pCMV-dR8.2 dvpr, and pCMV-VSVG with ScreenFect (Wako). U87 cells were infected with lentivirus with polybrene (8 μg/ml) for 6 hrs, and then selected with puromycin (0.7 μg/ml) for 7 days, then maintained in puromycin (0.2 μg/ml).
Myc shRNA and control shRNA Cell line Generation
To knockdown MYC, MGG4 and H1975 cells were infected with GIPZ Lentiviral Human MYC shRNA (V2LHS_152053, GE Dharmacon) in polybrene (8 μg/ml) for 8 hrs. Two week later, cells were selected with puromycin (0.3μg/ml) for 5 days. To knockdown MYCN, IMR-32 cells were infected with GIPZ Lentiviral Human MYCN shRNA (V2LHS_36751, GE Dharmacon) in polybrene (8 μg/ml) for 8hrs. Three weeks later, cells were selected with puromycin (0.3 μg/ml) for 7 days. GIPZ Non-silencing Lentiviral shRNA Control (RHS4348, GE Dharmacon) was used as control.
Fluorescence in situ Hybridization
Gene amplification status of MYC and MYCN was evaluated by fluorescence in situ hybridization (FISH). BAC clones CTD-3066D1 and RP11-480N14 were used to make the MYC and MYCN probes, respectively, and BAC clones RP11-301H15 (Chr8) and RP11-984I21 (Chr2) were used for centromere controls. The probes were labeled in Cy3-dCTP or FITCdUTP. Gene-amplified cells were counted in at least 3 different high-power fields, and the proportion of amplification-positive per total cells was calculated. Gene/control probe copy number ratios of >2.0 were considered amplified.
Western Blot Analyses
Research. and Vinculin (Thermo Scientific).
Cell Viability and Cytotoxicity Analysis
To assess cell viability, GBM tumorspheres were dissociated into single cells and seeded into 96-well plates at 7,000-8,000 cells/well. After 12-24 hours, chemical inhibitors and/or NMN, NAD+, or NA were serially diluted and added to wells. Cell viability was measured by CellTiterGlo (Promega) assays and the IC 50 values (drug concentrations causing 50% viability of cells) were determined. To determine cytotoxicity, 7,000-8,000 cells were treated with DMSO, 12.5 nM of FK866 or GMX1778, and the number of viable cells that excluded trypan blue was counted using TE2000-U inverted microscope (Nikon) at 48, 72, and 96 hrs after treatment.
Apoptosis Analysis
GBM tumorspheres were dissociated into single cells and 1x10 5 (23) (24) (25) (26) . For the U87 assay, the amounts of each metabolite labeled at specific carbons were measured and C 3 or C 6 labeled carbons were used for analysis. For the MGG4 assay, the total amounts of each metabolite, both labeled and unlabeled, were measured and used for analysis. Data were expressed as pmol/1x10 6 cells.
Animal Studies
For GBM orthotopic xenograft survival experiments, 1x10 5 MGG8 cells were implanted into the right striatum of SCID mice as described (21) . After 5 days, animals were randomized to treatments with weekly oral gavage with GMX1778 (250 mg/kg) (n=7) or vehicle [20% Captisol (CyDex) and 5% dextrose in water] (n=7). Mice were monitored daily and body weight was 
Statistical Analyses
For parametric analyses, 2-tailed student t tests were used, and for analysis of frequencies of nominal data, 2-tailed Fisher exact test was used. Data were expressed as mean ± SE. Survival analysis was performed using the Kaplan-Meier method using the log-rank test to compare treatment arms. P values less than 0.05 were considered statistically significant. All in vitro and in vivo experiments, including cell viability assays, metabolite quantification, Western Blot, and flow cytometry, were performed at least twice to confirm reproducibility. 13 C metabolic flux analysis in Myc-transduced U87 GBM cells and MGG4 were also performed twice with at least 3 replicates per condition.
RESULTS
Overactive Myc Drives Aerobic Glycolysis in Glioblastoma Cells
Inappropriate Myc activation drives aerobic glycolysis ("Warburg effect") in part by inducing expression of key glycolytic pathway regulators (1, 17, 18, 27) . To evaluate the effect of overactive Myc on glycolysis in GBM cells, we applied (Figs. 1A, 1B) . Lentivirus constructs carrying either MYC or GFP driven by a constitutively active cytomegalovirus promoter were used to infect U87, generating U87-Myc and U87-GFP lines. Of note, Myc overexpression induced only a slight reduction in proliferation rate (Fig. 1C) . To gauge flux through glycolysis, both U87-Myc and U87-GFP were cultured in normoxia in the presence of [U- isotope enrichment in glycolytic metabolites was determined via capillary electrophoresis timeof-flight mass spectrometry (CE-TOFMS). The quantity of 13 C labeled glycolytic intermediates glucose 6-phosphate (G6P), fructose 6-phosphate (F6P, C 6 labeled), DHAP, pyruvate, and lactic acid (C 6 labeled) were significantly increased in U87-Myc compared to U87-GFP, indicating Myc overexpression increased glycolytic flux (Fig. 1D, Table S1 ). Additionally, Myc overexpression resulted in significantly increased expression of the glycolytic enzymes HKII, PKM2 and LDHA in U87 cells (Fig. 1E) .
We then tested whether inappropriate Myc activation would induce a dependence on glycolytic metabolism for growth. We assessed the effect of glucose deprivation on growth of cells with or without Myc overexpression. We found that U87-GFP cells survived significantly longer in glucose-free culture conditions than U87-Myc cells, indicating a switch to dependence on glucose for growth was generated when Myc was overexpressed (Fig. 1F) . Additionally, we inhibited glycolysis using 2-deoxyglucose (2-DG), a small molecule inhibitor of hexokinase (28), in U87-Myc and U87-GFP. Similar to our findings with glucose deprivation, growth of U87-Myc cells was more sensitive to glycolytic inhibition with 2-DG than U87-GFP (Fig. 1G ).
Glycolytic Inhibition is Selectively Toxic to MYC/MYCN amplified GBM Tumorspheres
We then tested the effect of glycolytic inhibition in a panel of patient-derived GBM tumorsphere lines, where Myc has been reported to play an important role in self-renewal and maintenance of tumorigenicity (3-6). We tested for MYC and MYCN gene copy number status by fluorescence in situ hybridization and expression of the respective proteins by Western blot. We found that 3 GBM tumorsphere lines in our panel had high-level amplification of MYC (MGG4)
or MYCN (MGG 6, MGG8) ( Fig. 2A) , and that all amplified lines had high-level expression of the corresponding proteins (Fig. 2B ). There were two lines that expressed Myc without MYC amplification (MGG18 and MGG91) (Figs. 2A, 2B ).
Research. We next tested the effect of 2-DG in our panel of GBM tumorspheres, and found that the MYC/MYCN amplified GBM tumorspheres were significantly more sensitive to the deleterious effects of 2-DG (Fig. 2C) . We then knocked down Myc expression in MGG4 (MYC amplified) using shRNA and tested the effects on glycolysis (Fig. 2D) . In contrast to Myc-overexpression, MYC knockdown inhibited expression of the glycolytic enzymes HKII, PKM2, and LDHA (Fig.   2E ). Stable Myc knockdown significantly decreased cell proliferation of MGG4 (Fig. 2F) .
However, after Myc knockdown we observed significantly enhanced survival of MGG4 in glucose-free culture and with exposure to 2-DG (Figs. 2G, 2H), confirming that Myc activity was a major contributor to the dependence of MGG4 on glycolysis for growth. We attempted to overexpress Myc in two non-MYC/MYCN amplified GBM tumorsphere lines, however stable lines could not be generated after Myc transduction. Although this may have been due to technical limitations, it is known that ecotpic Myc expression can invoke apoptosis in certain cell
To evaluate the contribution of MYCN to glycolytic dependency in a highly MYCN amplified cell line, we knocked down MYCN in IMR-32 cells (Figs. 2I, 2J ). Similar to results observed when knocking down MYC in a highly MYC amplified line, MYCN knockdown mildly decreased IMR-32 cell proliferation (Fig. 2K) . MYCN knockdown also inhibited expression of the glycolytic enzymes HKII, PKM2, and LDHA (Fig. 2J) . In addition, MYCN knockdown significantly decreased the sensitivity to the glycolysis inhibitor 2-DG (Fig. 2L) . These results indicate that MYCN is a driver of cell proliferation in IMR-32 and induces a dependence on glycolysis for cell growth.
Overactive Myc renders GBM cells vulnerable to glycolytic inhibition with NAMPT inhibitors
on
NAMPT is the rate-limiting enzyme of the NAD+ salvage pathway in eukaryotes, and its inhibition mediates cytotoxicity in cancer cells by attenuating glycolysis at the NAD+-requiring glyceraldehyde 3-phosphate dehydrogenase (GAPDH) step, among other metabolic perturbations (22, 29) . We therefore tested the effect of small molecule inhibitors of NAMPT in our panel of GBM tumorsphere lines. We tested two chemically distinct, highly specific NAMPT inhibitors, FK866 (30-32) and GMX1778 (33, 34) , on the growth of GBM tumorspheres. Both FK866 and GMX1778 significantly decreased NAD+ levels in both MYC/MYCN amplified and MYC/MYCN non-amplified GBM tumorspheres (Fig. S1A) . However, reduction of NAD+ with NAMPT inhibitors resulted in strikingly potent cytotoxicity in a MYC/MYCN-dependent manner. To test whether sensitivity to NAMPT inhibitors was mediated by Myc or N-Myc overactivity, we tested the effect of FK866 and GMX1778 in our MYC-transduced, MYC knockdown and MYCN knockdown systems. We found that MYC knockdown using shRNA significantly protected MYC amplified MGG4 from the cytotoxic effect of NAMPT inhibition (Fig. 3B) , and similarly MYCN knockdown protected highly MYCN amplified IMR-32 from NAMPT inhibitor cytotoxicity (Fig.   3C ). Correspondingly, Myc overexpression induced sensitivity to NAMPT inhibitors in U87 cells, which are completely resistant to NAMPT inhibitors at baseline (Fig. 3D) .
NAMPT Inhibitors Mediate Cytotoxicity in MYC/MYCN amplified GBM Tumorspheres by
Inhibiting Glycolysis
To confirm that NAMPT inhibitors inhibit glycolysis in Myc-driven GBM cells, we measured total levels of glycolytic intermediates in MGG4 (MYC amplified GBM tumorsphere line) with or
without NAMPT inhibitor using CE-TOFMS. Incubation with NAMPT inhibitor resulted in marked accumulation of glycolytic intermediates upstream of the GAPDH step [i.e., G6P, F6P, FBP, glyceraldehyde 3-phosphate (G3P) and DHAP] while glycolytic intermediates downstream of GAPDH were not significantly changed (3-phosphoglycerate and 2-phosphoglycerate) or decreased (pyruvate and lactic acid) (Fig. 4A, Table S3 ). These results indicated NAMPT inhibitor blocked glycolysis at the GAPDH step in MGG4. To determine whether the NAMPT inhibitor-induced glycolysis blockade observed in the MGG4 metabolic flux data was selective for MYC/MYCN amplified GBM cells, we used a second assay to quantify levels of DHAP, which rapidly and reversibly isomerizes with the GAPDH substrate G3P, in our panel of GBM tumorspheres with and without NAMPT inhibition. We found that NAMPT inhibitor exposure significantly increased the levels of DHAP in the MYC/MYCN amplified (and NAMPT inhibitor sensitive) GBM tumorsphere lines, whereas those in non-amplified tumorspheres were unchanged (Fig. 4B) . These data confirm that NAMPT inhibitors disrupt glycolysis at the NAD+-dependent GAPDH step in MYC/MYCN amplified GBM tumorspheres.
Myc Alters NAD+ Metabolism
Because NAMPT inhibitors deplete intracellular NAD+ to mediate their effects on tumor growth, we further studied the relationship between Myc and NAD+. Intriguingly, we discovered that MYC/MYCN amplified GBM tumorspheres had significantly lower basal intracellular NAD+ levels compared to non-amplified GBM (Figs. 5A , 5B). NAMPT inhibitor exposure significantly reduced the absolute NAD+ levels in both MYC/MYCN amplified and non-amplified lines, however NAD+ levels in amplified lines were nearly completely eliminated while the NAD+ levels in non-amplified lines after NAMPT inhibitor exposure remained higher than the basal We then tested the apparent association between Myc activity and NAD+ metabolism using our MYC/MYCN-knockdown and overexpression systems. Knockdown of MYC in MGG4 (MYC amplified) and MYCN in IMR-32 (MYCN amplified) resulted in increased intracellular NAD+ levels (Figs. 5C, 5D ), while overexpression of Myc in U87 cells resulted in significant reduction of NAD+ (Fig. 5E ). Similar to our observations in GBM tumorspheres (Figs. 5A , 5B), NAMPT inhibitor treatment significantly reduced NAD+ levels in both U87-GFP and U87-Myc cells (Figs. 5E, S2A), but the post-treatment levels in U87-GFP remained comparable to the pre-treatment (basal) levels in U87-Myc (Fig. 5E ), again suggesting a threshold NAD+ level for survival was maintained without Myc overactivity.
We then confirmed that the NAMPT inhibitor-mediated effects observed in Myc-driven GBM were dependent on both NAMPT and NAD+. Exogenous supplementation with NAD+ increased intracellular NAD+ levels and rescued U87-Myc and MYC/MYCN amplified cells from NAMPT inhibitor cytotoxicity (Figs. 5F-5I). Furthermore, MYC/MYCN amplified cells were rescued from NAMPT inhibitor cytotoxicity with nicotinamide mononucleotide (NMN), a product of the NAMPT reaction and a direct precursor of NAD+, indicating direct NAMPT inhibition (Fig S2B) . In contrast, supplementation with NA, a precursor for an alternate NAD+ salvage pathway ratelimited by nicotinic acid phosphoribosyltransferase (Naprt1), could not rescue cells from the effects of NAMPT inhibition (Fig. S2C) .
Because Myc has been reported to induce NAMPT expression (35) and Naprt1 expression is known to modulate sensitivity to NAMPT inhibitors (36, 37), we evaluated the expression of Naprt1 as well as NAMPT in our GBM tumorsphere lines. We found that NAMPT expression was similar in all GBM tumorsphere lines tested (Fig. S3A) . However, Naprt1 expression varied and was notably absent in all MYC/MYCN amplified GBM tumorspheres, while in non-amplified lines Naprt1 expression was highly variable and not clearly associated with Myc expression (Fig. S3A ). In addition, we found that neither forced overexpression or knockdown of Myc altered the expression of NAMPT or Naprt1 (Figs. S3B, S3C ). These results suggest NAMPT and Naprt1 expression per se do not absolutely determine sensitivity to NAMPT inhibitors in GBM tumorspheres. Together with the differences observed in glycolytic intermediates between MYC/MYCN amplified vs. Myc-expressing/non-MYC/MYCN amplified lines after GAPDH inhibition (Fig. 4B) , our findings point to MYC/MYCN genetic amplification, rather than expression of NAMPT, Naprt1 or Myc (without gene amplification), as critical for determining sensitivity to glycolytic inhibition.
Glycolytic Inhibition with NAMPT inhibitor Results in Apoptosis and Potent in vivo
Activity in Myc-driven GBM
Prior studies have revealed that NAMPT inhibitor-mediated glycolytic blockade causes intracellular depletion of NAD+ as well as ATP, resulting in metabolic perturbation and cytotoxicity (22) . We similarly found that NAMPT inhibitors caused ATP depletion and cell death in MYC/MYCN amplified GBM tumorspheres (Figs. 6A-6C ). Cytotoxicity was mediated by apoptosis, as indicated by significant increases in Annexin V staining and double staining for Annexin V and propidium iodide (PI) by flow cytometry, and caspase-3/7 activation after treatment with NAMPT inhibitor (Figs. 6C, S4A) . We further observed activation of the intracellular energy regulator AMPK, inhibition of mTOR signaling, and induction of PARP cleavage, indicating intracellular metabolic perturbation after NAMPT inhibition in MYC/MYCN amplified cells (Fig. S4B ), but not in MGG85 (MYC/MYCN non-amplified) cells (Fig. S4C) . To assess whether NAMPT inhibitors affected cell proliferation, we assessed Ki-67 expression in 6F ). In contrast, oral GMX1778 had no effect on the survival of mice bearing U87 orthotopic xenografts (Fig. 6G) .
Myc-driven Cancers Are Sensitive to NAMPT Inhibitors
To explore whether our finding that Myc-driven GBM cells are selectively sensitive to glycolytic inhibition is generalizable to other cancer types, we tested the effect of NAMPT inhibitors in several standard cell lines from multiple cancer types known to harbor genetically activated (Figs. S7A-S7C ). Tumors from mice treated with GMX1778 had increased TUNEL staining (Fig. S7D ) and tumor regressions were observed the day after the weekly dose (Fig. S7A) . Notably, detectable NAD+ was nearly eliminated in tumors from GMX1778-treated mice (Fig. S7E ). All animals with flank or intracerebral xenografts tolerated oral GMX1778 well, with no significant body weight change or apparent toxicities during treatment (Figs. S8A-S8B ).
DISCUSSION
Here, we demonstrate that overactive Myc drives an abnormal metabolic program in GBM cells, increasing glycolytic flux and altering NAD+ metabolism. We found that Myc-driven GBM cells are sensitive to inhibition of the Myc-induced increased glycolytic drive, and identified NAMPT inhibitors, which attenuate glycolysis by depleting NAD+ required for the GAPDH step, as a selective and strikingly potent strategy for MYC/MYCN amplified GBM, Ultimately, our findings support and extend on the work of others that have demonstrated that overactive Myc generates an altered metabolic state in cancer cells that can be exploited by identifying their addiction to specific metabolites (19, 38) .
Research. It is now clear that GBM represents a group of molecularly heterogeneous subtypes with distinct clinical phenotypes (9) (10) (11) and that therapeutic development strategies must focus on specific biological subtypes in order to derive maximal benefit. Our strategy would target a small proportion of primary GBM, as approximately 4% of primary GBMs harbor high-level MYC or MYCN amplification (7-11). However, most large scale genetic studies have focused on primary (initial) GBM tumors and the few comprehensive studies that analyzed the genetic changes at develop at recurrence included only small numbers of paired tumors (39, 40) . The prevalence of MYC/MYCN copy number alterations developing at recurrence in primary GBM is unclear.
Interestingly, recent large-scale molecular studies of isocitrate dehydrogenase 1 (IDH1) and IDH2 mutant gliomas have identified a high proportion of MYC amplification (up to 31%) in this subtype of glioma (41) (42) (43) (44) . Although most MYC amplification events were low-level in these studies, the majority were observed at progression (44) and in the non-1p/19q codeleted subtype (43) , suggesting an association with more aggressive clinical behavior in IDH1/2 mutant gliomas (45) . Thus, our strategy could apply to a significant proportion of glioma subtypes.
We also identified an intriguing association between overactive Myc and reduced NAD+ levels, suggesting Myc reprograms NAD+ metabolism. Our findings contrast with a prior study that showed Myc induced expression of NAMPT and resulted in increased NAD+ levels (35) . In our study, Myc overexpression and knockdown had no effect on NAMPT expression, and increased Myc led to lower NAD+ levels. The reasons for this discrepancy are unclear and may relate to cell context, as all our NAD+ measurements were performed in malignant cells. NAD+ is a fundamental metabolite for numerous critical intracellular pathways and further studies will be needed to elucidate the complex mechanisms of NAD+ regulation, the effects of NAMPT inhibition and the relationship between Myc and NAD+. Intriguingly, we found evidence that a critical NAD+ threshold may exist for cancer cell survival. This preliminary finding warrants further detailed investigation since together with our observation that NAMPT inhibitors nearly 
completely eliminate detectable NAD+ levels in xenograft tumors, our data suggests intratumoral NAD+ level represents a potential predictive and/or pharmacodynamic biomarker in Myc-driven cancers.
It is likely that other genetic or epigenetic alterations that similarly impact cancer cell metabolism may also sensitize to NAMPT inhibitors, as NAMPT inhibitor activity has been observed in diverse cancer types (34, 46) . Whether increased Myc/N-Myc expression without MYC/MYCN genetic alteration sensitizes to glycolytic inhibition remains to be completely determined. We found that the association with glycolytic inhibitor sensitivity in GBM cells was most tightly 
